Vutrisiran

Vutrisiran is the medicine in Amvuttra, a solution for injection under the skin. The US label calls it a transthyretin-directed small interfering RNA, and says it causes degradation of the messenger RNA for transthyretin (TTR) through RNA interference, which reduces TTR protein and its deposits in tissues. The label lists two indications in adults: the polyneuropathy of hereditary transthyretin-mediated amyloidosis, and the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. The atlas holds no trial results for it.

Also called Amvuttra · Vutrisiran sodium

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 2604578 (vutrisiran); the label names the salt vutrisiran sodium, whose UNII 28O0WP6Z1P is a broad match to the ingredient. RxClass lists the FDA established pharmacologic classes Small Interfering RNA and Transthyretin-directed RNA Interaction, so the record is filed under the class page on the second. MeSH has no descriptor for vutrisiran (an exact-label lookup returned an empty list on 2026-11-19). The label read is the Alnylam Pharmaceuticals, Inc. label for Amvuttra, application NDA215515, effective 2025-11-06 in openFDA; it is the only openFDA label returned for the ingredient, and Drugs@FDA lists one application with one product. The record read has no boxed warning section. This page records the label indications, the class and the mechanism sentence only: no trial result and no dose is given.

About this drug

Level
Substance
Mechanism
The label says vutrisiran is a double-stranded siRNA-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.

Classification codes

  • UNII 28O0WP6Z1P Vutrisiran sodium

Claims and evidence

Context Adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis, or with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, as described in the US label of Amvuttra

Recipient
Recipient not specified
Population
Adults in the two groups the indications section of the label names: adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis, and adults with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis. The passages read give no other age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN)
  • Adults with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM)
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Amvuttra (vutrisiran injection; Alnylam Pharmaceuticals, Inc., application NDA215515; the version dated 2025-11-06 in openFDA) calls the product a transthyretin-directed small interfering RNA. It lists two indications in adults: the polyneuropathy of hereditary transthyretin-mediated amyloidosis, and the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.

    Applies to Recipient not specified Adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis, or with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, as described in the US label of Amvuttra

    Certainty method
    Not assessed
    Limitations
    This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The polyneuropathy indication concerns the nerves, not the heart, and the atlas gives it no page of its own. The label read has no boxed warning section. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-19
    Next evidence check due
    Not scheduled
    Sources and citations (5)
    1. Background openFDA drug label record for vutrisiran injection (Amvuttra), Alnylam Pharmaceuticals, Inc. label: indications, mechanism, class wording

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 8db0facb-81b6-4006-9239-27dc6409c5d3 (manufacturer Alnylam Pharmaceuticals, Inc., application NDA215515), returned on 2026-11-19. The label text is dated 2025-11-06 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Application number of the label read, NDA215515.
      Retrieved
      Source effective date
      2025-11-06
      Source state
      Current
      Version fingerprint
      4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for vutrisiran injection (Amvuttra), Alnylam Pharmaceuticals, Inc. label: indications, mechanism, class wording

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 8db0facb-81b6-4006-9239-27dc6409c5d3 (manufacturer Alnylam Pharmaceuticals, Inc., application NDA215515), returned on 2026-11-19. The label text is dated 2025-11-06 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20251106.
      Retrieved
      Source effective date
      2025-11-06
      Source state
      Current
      Version fingerprint
      4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for vutrisiran injection (Amvuttra), Alnylam Pharmaceuticals, Inc. label: indications, mechanism, class wording

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 8db0facb-81b6-4006-9239-27dc6409c5d3 (manufacturer Alnylam Pharmaceuticals, Inc., application NDA215515), returned on 2026-11-19. The label text is dated 2025-11-06 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].indications_and_usage[0], highlights sentence
      How it applies
      Label passage quoted in the research quote table (Q-W4K28-VUT-LB-04).
      Retrieved
      Source effective date
      2025-11-06
      Source state
      Current
      Version fingerprint
      4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record for vutrisiran injection (Amvuttra), Alnylam Pharmaceuticals, Inc. label: indications, mechanism, class wording

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 8db0facb-81b6-4006-9239-27dc6409c5d3 (manufacturer Alnylam Pharmaceuticals, Inc., application NDA215515), returned on 2026-11-19. The label text is dated 2025-11-06 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].indications_and_usage[0], section 1.2
      How it applies
      Label passage quoted in the research quote table (Q-W4K28-VUT-LB-05).
      Retrieved
      Source effective date
      2025-11-06
      Source state
      Current
      Version fingerprint
      4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    5. Supports openFDA drug label record for vutrisiran injection (Amvuttra), Alnylam Pharmaceuticals, Inc. label: indications, mechanism, class wording

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 8db0facb-81b6-4006-9239-27dc6409c5d3 (manufacturer Alnylam Pharmaceuticals, Inc., application NDA215515), returned on 2026-11-19. The label text is dated 2025-11-06 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].indications_and_usage[0], section 1.1
      How it applies
      Label passage quoted in the research quote table (Q-W4K28-VUT-LB-06).
      Retrieved
      Source effective date
      2025-11-06
      Source state
      Current
      Version fingerprint
      4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:vutrisiran
Content hash
ac42f7425d7305845a0d90f50c84e34d55a513a3b095867d83d88057d404bc23